190 related articles for article (PubMed ID: 35676636)
1. Real-World experience of interictal burden and treatment in migraine: a qualitative interview study.
Lo SH; Gallop K; Smith T; Powell L; Johnston K; Hubig LT; Williams E; Coric V; Harris L; L'Italien G; Lloyd AJ
J Headache Pain; 2022 Jun; 23(1):65. PubMed ID: 35676636
[TBL] [Abstract][Full Text] [Related]
2. Measuring interictal burden among people affected by migraine: a descriptive survey study.
Hubig LT; Smith T; Williams E; Powell L; Johnston K; Harris L; L'Italien G; Coric V; Lloyd AJ; Lo SH
J Headache Pain; 2022 Aug; 23(1):97. PubMed ID: 35941572
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis.
Gaul C; Seidel K; Heuck A; Silaidos C; Mrosowsky T; Eberhardt A; Fritz B; Jacob C
J Med Econ; 2023; 26(1):667-678. PubMed ID: 37126606
[TBL] [Abstract][Full Text] [Related]
4. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
5. Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review.
Rhyne C; Cohen JM; Seminerio MJ; Carr K; Krasenbaum LJ
Medicine (Baltimore); 2023 Jun; 102(23):e33874. PubMed ID: 37335663
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
7. Assessment and treatment of the burden of migraine: a case series.
Bryson J; Buse DC; Lipton RB
Neurologist; 2010 Jul; 16(4):254-61. PubMed ID: 20592569
[TBL] [Abstract][Full Text] [Related]
8. A stated preference survey to explore patient preferences for novel preventive migraine treatments.
Hubig LT; Smith T; Chua GN; Lloyd AJ; Powell L; Johnston K; Harris L; L'Italien G; Coric V; Lo SH
Headache; 2022 Oct; 62(9):1187-1197. PubMed ID: 36047857
[TBL] [Abstract][Full Text] [Related]
9. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
Foster SA; Hoyt M; Ye W; Mason O; Ford JH
Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
[TBL] [Abstract][Full Text] [Related]
10. Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience.
Silvestro M; Tessitore A; Orologio I; De Micco R; Tartaglione L; Trojsi F; Tedeschi G; Russo A
J Headache Pain; 2022 Jun; 23(1):69. PubMed ID: 35698070
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
Driessen MT; Cohen JM; Thompson SF; Patterson-Lomba O; Seminerio MJ; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 May; 23(1):56. PubMed ID: 35578182
[TBL] [Abstract][Full Text] [Related]
12. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
Sevivas H; Fresco P
Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.
Bigal ME; Walter S
CNS Drugs; 2014 May; 28(5):389-99. PubMed ID: 24638916
[TBL] [Abstract][Full Text] [Related]
14. [Novel migraine treatment with CGRP-related monoclonal antibodies].
Shibata M
Rinsho Shinkeigaku; 2020 Oct; 60(10):668-676. PubMed ID: 32893246
[TBL] [Abstract][Full Text] [Related]
15. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
Eur J Neurol; 2022 May; 29(5):1505-1513. PubMed ID: 35098620
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
17. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.
Torres-Ferrús M; Gallardo VJ; Alpuente A; Caronna E; Gine-Cipres E; Pozo-Rosich P
J Neurol; 2021 Oct; 268(10):3789-3798. PubMed ID: 33772636
[TBL] [Abstract][Full Text] [Related]
18. CGRP antagonists for decreasing migraine frequency: New options, long overdue.
Bucklan J; Ahmed Z
Cleve Clin J Med; 2020 Apr; 87(4):211-218. PubMed ID: 32238376
[TBL] [Abstract][Full Text] [Related]
19. Role of CGRP in Migraine.
Edvinsson L
Handb Exp Pharmacol; 2019; 255():121-130. PubMed ID: 30725283
[TBL] [Abstract][Full Text] [Related]
20. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
